Regorafenib improves survival in advanced HCC patients progressing on sorafenib
03 Sep 2020
byStephen Padilla
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.